Please assess the completion status of the following clinical trial:

Trial Title: Lapatinib and Paclitaxel in Treating Patients With Advanced Solid Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed solid tumor, including the following tumor types:~  * Breast cancer~ * Non-small cell lung cancer~ * Prostate cancer~ * Bladder cancer~ * Gastroesophageal junction cancer~ * Ovarian cancer~ * Germ cell tumor~* Advanced or metastatic disease~* No effective curative therapy exists~* Evaluable disease~  * Measurable disease not required~ * Bone-only disease allowed~* No progressing brain metastases~PATIENT CHARACTERISTICS:~* ECOG performance status 0-2~* Life expectancy \> 3 months~* Absolute neutrophil count ≥ 1,500/mm\^3~* Hemoglobin ≥ 9.0 g/dL~* Platelet count ≥ 100,000/mm\^3~* Bilirubin normal~* AST/ALT ≤ 2.5 times upper limit of normal~* Creatinine normal~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* No serious intercurrent medical or psychiatric illness~* No serious active infection~* No gastrointestinal tract disease that would impair a patient's ability to take oral medication~* No history of significant cardiac disease, including any of the following:~  * Congestive heart failure~ * Symptomatic cardiac arrhythmias~ * Unstable angina~* No pre-existing peripheral neuropathy ≥ 2~PRIOR CONCURRENT THERAPY:~* Any number of prior therapies allowed~* Prior paclitaxel, tyrosine kinase inhibitor therapy, or endothelial growth factor inhibitors allowed~* At least 14 days since prior and no concurrent CYP3A4 inducers or herbal or dietary supplements~* At least 7 days since prior and no concurrent CYP3A4 inhibitors~* At least 6 months since prior and no concurrent amiodarone~* More than 1 month since prior chemotherapy, radiotherapy, hormonal therapy, or investigational anticancer agents~* Concurrent continued use of gonadal suppression agents (i.e., goserelin acetate or leuprolide acetate) allowed~* No antacids 1 hour before and after study drug administration~* No concurrent retinoids~* No concurrent hormonal anticancer agent~* No other concurrent anticancer chemotherapy or investigational anticancer agents

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lapatinib and Paclitaxel (Type: EXPERIMENTAL): Lapatinib will be self-administered orally on days 1 and 2 of weeks 1, 2, and 3 of a 4-week cycle. Lapatinib is the experimental therapy and is being administered using a dose escalation design guided by careful monitoring of toxicities. Abraxane will be administered IV weekly on day 3 of weeks 1, 2, and 3 of a 4-week cycle. Abraxane is being administered at the well tolerated and effective standard dose and schedule of 100mg/m2 weekly 3 out of 4 weeks as defined by previous phase I and II studies. Patients will continue on therapy as long as they are not experiencing toxicities and there is no evidence of disease progression.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete